References
- Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895–905.
- Areethamsirikul N, Masih-Khan E, Chu CM, et al. CyBorD induction therapy in clinical practice. Bone Marrow Transplant 2015; 50: 375–379.
- Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909–923.
- Gebauer N, Biersack H, Czerwinska AC, et al. Favourable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents – a single centre perspective. Leuk Lymphoma 2015. [Epub ahead of print]. doi: 10.3109/10428194.2015.1046863.
- Zhang W, Winder T, Ning Y, et al. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011; 22: 104–109.
- Gebauer N, Bernard V, Gebauer W, et al. MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis. Acta Haematol 2013; 129: 251–256.
- Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
- Toffoli G, Biason P, Russo A, et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res 2009; 15: 3550–3556.
- Ortega MM, Honma HN, Zambon L, et al. GSTM1 and codon 72 P53 polymorphism in multiple myeloma. Ann Hematol 2007; 86: 815–819.
- Hattori Y, Ikeda Y, Suzuki Y, et al. Codon 72 polymorphism of TP53 gene is a novel prognostic marker for therapy in multiple myeloma. Br J Haematol 2014; 165: 728–731.